董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Freda Lewis Hall | 女 | Independent Director | 71 | 未披露 | 未持股 | 2026-08-18 |
| Paul Glavine | 男 | Chief Growth Officer and Director | 37 | 未披露 | 29.97 | 2026-08-18 |
| Eric So | 男 | Director, President | 50 | 未披露 | 31.11 | 2026-08-18 |
| Theresa Firestone | 女 | Independent Director | 70 | 未披露 | 2.61 | 2026-08-18 |
| Grant Froese | 男 | Independent Director | 64 | 未披露 | 3.03 | 2026-08-18 |
| Eric Hoskins | 男 | Independent Director | 65 | 未披露 | 2.76 | 2026-08-18 |
| Mark Lawson | 男 | Independent Director | 53 | 未披露 | 2.80 | 2026-08-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Glavine | 男 | Chief Growth Officer and Director | 37 | 未披露 | 29.97 | 2026-08-18 |
| Eric So | 男 | Director, President | 50 | 未披露 | 31.11 | 2026-08-18 |
| Greg Cavers | 男 | Chief Financial Officer | 56 | 未披露 | 1.90 | 2026-08-18 |
| Gabriel Fahel | 男 | Chief Legal Officer and Corporate Secretary | 51 | 未披露 | 3.85 | 2026-08-18 |
| Aaron Bartlone | 男 | Chief Operating Officer | 59 | 未披露 | 3.43 | 2026-08-18 |
| George Tziras | 男 | Chief Business Officer | 45 | 未披露 | 3.63 | 2026-08-18 |
| Amir Inamdar | 男 | Chief Medical Officer | 52 | 未披露 | 2.02 | 2026-08-18 |
| Michael Halstead | 男 | Chief Executive Officer | -- | 未披露 | 未持股 | 2026-08-18 |
| Regina Donohue | 女 | Chief People Officer | -- | 未披露 | 未持股 | 2026-08-18 |
董事简历
中英对照 | 中文 | 英文- Freda Lewis Hall
-
Freda Lewis Hall自2019年11月以来一直担任我们的董事会成员。自2019年1月以来，Lewis-Hall博士一直担任制药公司辉瑞公司的首席病人官兼执行Vice President。从2009年到2019年1月，Lewis-Hall博士担任辉瑞首席医疗官。在2009年加入辉瑞之前，Lewis-Hall博士曾于2008年6月至2009年5月在生物制药公司Vertex Pharmaceuticals，Inc.和高级副总裁，U.S.Pharmaceuticals担任多个高级领导职位，包括首席医疗官和执行Vice President，Bristol-Myers Squibb Co.的医疗事务（从2003年到2008年5月）。自2017年8月以来，Lewis-Hall博士一直担任生物制药公司SpringWorksTherapeutics，Inc.的董事会成员。2014年12月至2017年5月，她担任梦百合服务公司泰尼特保健公司的董事会成员。Lewis-Hall博士在约翰霍普金斯大学（Johns Hopkins University）获得自然科学学士学位，在霍华德大学医学院（Howard University College of Medicine）获得医学博士学位。
Freda Lewis Hall has served as a member of Board since September 2023. She served as Senior Medical Advisor to the CEO of Pfizer Inc., or Pfizer, from December 2019 until her retirement in March 2020. Before assuming that responsibility, beginning January 2019, Dr. Lewis Hall served as Chief Patient Officer and Executive Vice President of Pfizer. Dr. Lewis Hall served as Pfizer's Chief Medical Officer from 2009 to January 2019. Prior to joining Pfizer in 2009, Dr. Lewis Hall held various senior leadership positions including Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals Incorporated from June 2008 to May 2009; Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol Myers Squibb Company from 2003 until May 2008; Vice President Research and Development at Pharmacia Corporation from 2002 2003; Product Team Leader at Pharmacia and Eli Lilly and Company from 1998 to 2002; Director of Lilly Center for Women's Health from 1996 1999; and Clinical Research Physician at Eli Lilly from 1994 through 1996. In October 2021, Dr. Lewis Hall became a member of the board of directors for Pyxis Oncology (Nasdaq: PYXS), (where she serves as a member of the Nominating and Corporate Governance Committee); she serves as a member of the board of directors for Milliken & Company since July 2019, as a member of the Audit and HR and Compensation Committees; and as a member of the board of directors of SpringWorks Therapeutics, Inc. (Nasdaq GS: SWTX) since 2017, where she serves as the chair of the Nominating and Governance Committee and as a member of the audit committee. Dr. Lewis Hall served as a member of the board of directors for Exact Sciences Corporation (Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the Human Capital and Innovation, Technology and Pipeline Committees; a member of 1LifeHealthcare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the Nominating and Corporate Governance Committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC) from 2014 to 2017. - Freda Lewis Hall自2019年11月以来一直担任我们的董事会成员。自2019年1月以来，Lewis-Hall博士一直担任制药公司辉瑞公司的首席病人官兼执行Vice President。从2009年到2019年1月，Lewis-Hall博士担任辉瑞首席医疗官。在2009年加入辉瑞之前，Lewis-Hall博士曾于2008年6月至2009年5月在生物制药公司Vertex Pharmaceuticals，Inc.和高级副总裁，U.S.Pharmaceuticals担任多个高级领导职位，包括首席医疗官和执行Vice President，Bristol-Myers Squibb Co.的医疗事务（从2003年到2008年5月）。自2017年8月以来，Lewis-Hall博士一直担任生物制药公司SpringWorksTherapeutics，Inc.的董事会成员。2014年12月至2017年5月，她担任梦百合服务公司泰尼特保健公司的董事会成员。Lewis-Hall博士在约翰霍普金斯大学（Johns Hopkins University）获得自然科学学士学位，在霍华德大学医学院（Howard University College of Medicine）获得医学博士学位。
- Freda Lewis Hall has served as a member of Board since September 2023. She served as Senior Medical Advisor to the CEO of Pfizer Inc., or Pfizer, from December 2019 until her retirement in March 2020. Before assuming that responsibility, beginning January 2019, Dr. Lewis Hall served as Chief Patient Officer and Executive Vice President of Pfizer. Dr. Lewis Hall served as Pfizer's Chief Medical Officer from 2009 to January 2019. Prior to joining Pfizer in 2009, Dr. Lewis Hall held various senior leadership positions including Chief Medical Officer and Executive Vice President, Medicines Development at Vertex Pharmaceuticals Incorporated from June 2008 to May 2009; Senior Vice President, U.S. Pharmaceuticals, Medical Affairs for Bristol Myers Squibb Company from 2003 until May 2008; Vice President Research and Development at Pharmacia Corporation from 2002 2003; Product Team Leader at Pharmacia and Eli Lilly and Company from 1998 to 2002; Director of Lilly Center for Women's Health from 1996 1999; and Clinical Research Physician at Eli Lilly from 1994 through 1996. In October 2021, Dr. Lewis Hall became a member of the board of directors for Pyxis Oncology (Nasdaq: PYXS), (where she serves as a member of the Nominating and Corporate Governance Committee); she serves as a member of the board of directors for Milliken & Company since July 2019, as a member of the Audit and HR and Compensation Committees; and as a member of the board of directors of SpringWorks Therapeutics, Inc. (Nasdaq GS: SWTX) since 2017, where she serves as the chair of the Nominating and Governance Committee and as a member of the audit committee. Dr. Lewis Hall served as a member of the board of directors for Exact Sciences Corporation (Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the Human Capital and Innovation, Technology and Pipeline Committees; a member of 1LifeHealthcare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the Nominating and Corporate Governance Committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC) from 2014 to 2017.
- Paul Glavine
-
Paul Glavine是该公司的联合创始人和首席运营官。他是一位连续创业者和投资者，在生物技术、采矿、技术和生命科学领域拥有丰富的经验。Glavine先生是TruVerra的联合创始人，该公司被Supreme Cannabis Company收购，后来又被Canopy Growth收购。他之前的背景是从事停车技术行业，过去5年间，他曾为1.8亿人次的并购及其他融资提供咨询服务。
Paul Glavine is a biotechnology entrepreneur and investor leading growth at Helus Pharma, a clinical stage biopharmaceutical company developing novel serotonergic agonists for mental healthcare. Under his leadership, Helus Pharma secured FDA Breakthrough Therapy Designation for HLP003 and advanced HLP004, a generalized anxiety disorder candidate, from preclinical studies into human trials. A serial entrepreneur, Mr. Glavine has raised over $500 million in capital and led mergers and acquisitions that have expanded operating businesses and therapeutic pipelines across his portfolio. He serves as Chairman of LongPoint ETFs. He is a Milken Institute Young Leader and was named to Catalyst Health's Top 40 Under 40 in Life Sciences. - Paul Glavine是该公司的联合创始人和首席运营官。他是一位连续创业者和投资者，在生物技术、采矿、技术和生命科学领域拥有丰富的经验。Glavine先生是TruVerra的联合创始人，该公司被Supreme Cannabis Company收购，后来又被Canopy Growth收购。他之前的背景是从事停车技术行业，过去5年间，他曾为1.8亿人次的并购及其他融资提供咨询服务。
- Paul Glavine is a biotechnology entrepreneur and investor leading growth at Helus Pharma, a clinical stage biopharmaceutical company developing novel serotonergic agonists for mental healthcare. Under his leadership, Helus Pharma secured FDA Breakthrough Therapy Designation for HLP003 and advanced HLP004, a generalized anxiety disorder candidate, from preclinical studies into human trials. A serial entrepreneur, Mr. Glavine has raised over $500 million in capital and led mergers and acquisitions that have expanded operating businesses and therapeutic pipelines across his portfolio. He serves as Chairman of LongPoint ETFs. He is a Milken Institute Young Leader and was named to Catalyst Health's Top 40 Under 40 in Life Sciences.
- Eric So
-
Eric So是该公司的联合创始人和总裁。在过去15年中，他是各种公共和私营公司的资深所有者和经营者，并在从初创企业到高增长和跨国企业的商业生命周期的各个阶段领导C级公司战略、发展和财务。他的职业生涯始于Torys LLP的公司商业、证券、金融和并购领域。
Eric So is a veteran founder and operator of various public and private companies over the last 20 years and has led corporate strategy, development and finance at all stages of the business life cycle from start up to high growth and large multi national. A trusted advisor he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm. He has focused on sectors which have profound global impact in critical areas such as mental health and addiction. - Eric So是该公司的联合创始人和总裁。在过去15年中，他是各种公共和私营公司的资深所有者和经营者，并在从初创企业到高增长和跨国企业的商业生命周期的各个阶段领导C级公司战略、发展和财务。他的职业生涯始于Torys LLP的公司商业、证券、金融和并购领域。
- Eric So is a veteran founder and operator of various public and private companies over the last 20 years and has led corporate strategy, development and finance at all stages of the business life cycle from start up to high growth and large multi national. A trusted advisor he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm. He has focused on sectors which have profound global impact in critical areas such as mental health and addiction.
- Theresa Firestone
-
Theresa Firestone是一位资深医疗保健高管，拥有零售、制药、健康和保健、政府和全球重组方面的专业知识。她在辉瑞公司担任了15年的高级职务，在政府部门工作了14年，在零售和保健部门工作了7年。Firestone女士拥有在加拿大、欧洲和亚洲担任行政领导职务的国际经验和丰富的损益表经验。在辉瑞，费尔斯通女士是亚洲新兴市场区域总裁，负责1.4B美元的损益表，并负责管理亚洲的9个市场。费尔斯通女士最近担任Shoppers Drug Mart的高级副总裁，负责领导健康和保健计划，包括新的增长战略以及健康诊所和PC Health App的开发和推出。
Theresa Firestone is a senior healthcare executive with over 35 years' experience in pharmaceuticals, health & wellness and government and has extensive P&L, strategy development and operations expertise. Ms. Firestone has held executive leadership positions in Canada, Europe and Asia and led teams in 15 different countries. Prior to retirement in 2021, she was Senior Vice President, Health and Wellness at Shoppers Drug Mart (SDM), Canada's largest retail pharmacy chain. Prior to Shoppers, Ms. Firestone was Regional President of Emerging Markets Asia with Pfizer Inc (Shanghai and HK). She was also General Manager of the Established Products Business Unit, Pfizer Canada, Country Manager, Pfizer Austria, VP Sales and VP of Government Affairs with Pfizer Canada. She currently sits on a number of Boards, including Apotex, Prollenium Medical Technologies, adMare BioInnovations and Blue Charm Adherence. - Theresa Firestone是一位资深医疗保健高管，拥有零售、制药、健康和保健、政府和全球重组方面的专业知识。她在辉瑞公司担任了15年的高级职务，在政府部门工作了14年，在零售和保健部门工作了7年。Firestone女士拥有在加拿大、欧洲和亚洲担任行政领导职务的国际经验和丰富的损益表经验。在辉瑞，费尔斯通女士是亚洲新兴市场区域总裁，负责1.4B美元的损益表，并负责管理亚洲的9个市场。费尔斯通女士最近担任Shoppers Drug Mart的高级副总裁，负责领导健康和保健计划，包括新的增长战略以及健康诊所和PC Health App的开发和推出。
- Theresa Firestone is a senior healthcare executive with over 35 years' experience in pharmaceuticals, health & wellness and government and has extensive P&L, strategy development and operations expertise. Ms. Firestone has held executive leadership positions in Canada, Europe and Asia and led teams in 15 different countries. Prior to retirement in 2021, she was Senior Vice President, Health and Wellness at Shoppers Drug Mart (SDM), Canada's largest retail pharmacy chain. Prior to Shoppers, Ms. Firestone was Regional President of Emerging Markets Asia with Pfizer Inc (Shanghai and HK). She was also General Manager of the Established Products Business Unit, Pfizer Canada, Country Manager, Pfizer Austria, VP Sales and VP of Government Affairs with Pfizer Canada. She currently sits on a number of Boards, including Apotex, Prollenium Medical Technologies, adMare BioInnovations and Blue Charm Adherence.
- Grant Froese
-
格兰特弗罗斯在加拿大零售巨头Loblaw Companies Limited完成了38年的职业生涯，他最后一次担任首席运营官直到退休。在Loblaw的职业生涯中，他领导运营、销售，并监督供应链、电子商务和营销职能。最近，格兰特是Harvest One的首席执行官。格兰特是灰狼管理服务公司的首席顾问，也是多家公司的董事会成员。
Grant Froese completed a 38 year career with Canadian retail giant Loblaw Companies Limited where he last served as Chief Operating Officer until his retirement. During his career at Loblaw, he led operations, merchandising and had oversight of supply chain, ecommerce, and marketing functions. After retirement Grant was the CEO of Harvest One / Delivra Health Brands until 2020. Currently, Grant is the principal consultant at Grey Wolf Management Services Inc. and sits on the board of several companies. - 格兰特弗罗斯在加拿大零售巨头Loblaw Companies Limited完成了38年的职业生涯，他最后一次担任首席运营官直到退休。在Loblaw的职业生涯中，他领导运营、销售，并监督供应链、电子商务和营销职能。最近，格兰特是Harvest One的首席执行官。格兰特是灰狼管理服务公司的首席顾问，也是多家公司的董事会成员。
- Grant Froese completed a 38 year career with Canadian retail giant Loblaw Companies Limited where he last served as Chief Operating Officer until his retirement. During his career at Loblaw, he led operations, merchandising and had oversight of supply chain, ecommerce, and marketing functions. After retirement Grant was the CEO of Harvest One / Delivra Health Brands until 2020. Currently, Grant is the principal consultant at Grey Wolf Management Services Inc. and sits on the board of several companies.
- Eric Hoskins
-
埃里克霍斯金斯是Maverix Private Equity的合伙人。他是安大略省前卫生部长（2014-2018年），负责北美最大的医疗保健系统之一。他曾是安大略省议会的民选议员，在卫生、经济发展和贸易、儿童和青年服务以及移民等领域担任内阁职务。霍斯金斯博士是一名医生和公共卫生专家，在卫生保健和公共政策方面拥有30多年的经验。
Eric Hoskins is a Partner at Maverix Private Equity. He is the former Ontario Health Minister (2014 2018) responsible for one of the largest health care systems in North America. He is a former elected Member of Ontario Provincial Parliament holding Cabinet positions in Health, Economic Development and Trade, Children and Youth Services, and Immigration. Dr. Hoskins is a physician and public health specialist with more than thirty years' experience in health care and public policy. - 埃里克霍斯金斯是Maverix Private Equity的合伙人。他是安大略省前卫生部长（2014-2018年），负责北美最大的医疗保健系统之一。他曾是安大略省议会的民选议员，在卫生、经济发展和贸易、儿童和青年服务以及移民等领域担任内阁职务。霍斯金斯博士是一名医生和公共卫生专家，在卫生保健和公共政策方面拥有30多年的经验。
- Eric Hoskins is a Partner at Maverix Private Equity. He is the former Ontario Health Minister (2014 2018) responsible for one of the largest health care systems in North America. He is a former elected Member of Ontario Provincial Parliament holding Cabinet positions in Health, Economic Development and Trade, Children and Youth Services, and Immigration. Dr. Hoskins is a physician and public health specialist with more than thirty years' experience in health care and public policy.
- Mark Lawson
-
马克·劳森是一位经验丰富的企业财务主管，在并购、资本市场和公司治理领域拥有20年的领导经验，在北美和新兴市场都有双重业务。他在推动战略增长、监督复杂交易以及在上市公司董事会任职，专注于审计、风险和治理方面有着良好的业绩记录。自2025年11月起，Lawson担任PUR的首席增长官，PUR是一家获得认证的B公司，是基于自然的碳镶嵌解决方案的全球领导者。2023年3月至2025年11月，他担任碳金融公司Invert Inc.的首席增长官。2022年9月至2024年12月，他担任能源转型公司Twenty20 Energy的董事长兼审计委员会主席。在此之前，2009年1月至2023年2月，他是Four Paths Partners的管理合伙人，这是一家专注于能源、能源转型和技术领域的主要投资和投资银行咨询公司。自2020年11月起，Lawson先生还担任临床阶段神经精神病学公司Helus Pharma（纳斯达克：HELP）的董事和审计与交易委员会主席。Lawson先生于加拿大西安大略大学获得统计科学文学士学位，并于加拿大西安大略大学Richard Ivey商学院获得MBA学位。作为一名前精英运动员，他是不败、西安大略大学野马全国锦标赛足球队的联合队长，以及西安大略大学大学校队田径冠军墙的入选者。Lawson先生还担任Hugh & Ilene Lawson慈善组织（HILCO）的董事会成员，该组织支持为追求高等教育的学生提供包容性教育机会。
Mark Lawson is an experienced corporate finance executive with 20 years of leadership in M&A, capital markets, and corporate governance, dually within the North America and the emerging markets. He has a proven track record of driving strategic growth, overseeing complex transactions, and serving on public company boards with a focus on audit, risk, and governance.Mr. Lawson has served as Chief Growth Officer of PUR, a certified B Corp and global leader in nature based carbon insetting solutions, since November 2025. From March 2023 to November 2025, he was Chief Growth Officer of Invert Inc., a carbon finance company. From September 2022 to December 2024, he was Chairman and Audit Committee Chair of Twenty20 Energy, an energy transition company. Prior to that, from January 2009 to February 2023, he was Managing Partner of Four Paths Partners, a principal investing and investment banking advisory firm focused on the energy, energy transition, and technology sectors. Mr. Lawson has also served as a Director and Chair of the Audit & Transaction Committee of Helus Pharma (Nasdaq: HELP), a clinical stage neuropsychiatry company, since November 2020.Mr. Lawson received his Bachelor of Arts in Statistical Sciences from The University of Western Ontario, Canada, and his MBA from The Richard Ivey School of Business, University of Western Ontario, Canada. A former elite athlete, he was Co Captain of the undefeated, University of Western Ontario Mustangs National Championship Football Team, and an Inductee into the University of Western Ontario Varsity Athletics Wall of Champions. Mr. Lawson also serves on the board of the Hugh & Ilene Lawson Charitable Organization (HILCO), which supports inclusive educational opportunities for students pursuing higher education. - 马克·劳森是一位经验丰富的企业财务主管，在并购、资本市场和公司治理领域拥有20年的领导经验，在北美和新兴市场都有双重业务。他在推动战略增长、监督复杂交易以及在上市公司董事会任职，专注于审计、风险和治理方面有着良好的业绩记录。自2025年11月起，Lawson担任PUR的首席增长官，PUR是一家获得认证的B公司，是基于自然的碳镶嵌解决方案的全球领导者。2023年3月至2025年11月，他担任碳金融公司Invert Inc.的首席增长官。2022年9月至2024年12月，他担任能源转型公司Twenty20 Energy的董事长兼审计委员会主席。在此之前，2009年1月至2023年2月，他是Four Paths Partners的管理合伙人，这是一家专注于能源、能源转型和技术领域的主要投资和投资银行咨询公司。自2020年11月起，Lawson先生还担任临床阶段神经精神病学公司Helus Pharma（纳斯达克：HELP）的董事和审计与交易委员会主席。Lawson先生于加拿大西安大略大学获得统计科学文学士学位，并于加拿大西安大略大学Richard Ivey商学院获得MBA学位。作为一名前精英运动员，他是不败、西安大略大学野马全国锦标赛足球队的联合队长，以及西安大略大学大学校队田径冠军墙的入选者。Lawson先生还担任Hugh & Ilene Lawson慈善组织（HILCO）的董事会成员，该组织支持为追求高等教育的学生提供包容性教育机会。
- Mark Lawson is an experienced corporate finance executive with 20 years of leadership in M&A, capital markets, and corporate governance, dually within the North America and the emerging markets. He has a proven track record of driving strategic growth, overseeing complex transactions, and serving on public company boards with a focus on audit, risk, and governance.Mr. Lawson has served as Chief Growth Officer of PUR, a certified B Corp and global leader in nature based carbon insetting solutions, since November 2025. From March 2023 to November 2025, he was Chief Growth Officer of Invert Inc., a carbon finance company. From September 2022 to December 2024, he was Chairman and Audit Committee Chair of Twenty20 Energy, an energy transition company. Prior to that, from January 2009 to February 2023, he was Managing Partner of Four Paths Partners, a principal investing and investment banking advisory firm focused on the energy, energy transition, and technology sectors. Mr. Lawson has also served as a Director and Chair of the Audit & Transaction Committee of Helus Pharma (Nasdaq: HELP), a clinical stage neuropsychiatry company, since November 2020.Mr. Lawson received his Bachelor of Arts in Statistical Sciences from The University of Western Ontario, Canada, and his MBA from The Richard Ivey School of Business, University of Western Ontario, Canada. A former elite athlete, he was Co Captain of the undefeated, University of Western Ontario Mustangs National Championship Football Team, and an Inductee into the University of Western Ontario Varsity Athletics Wall of Champions. Mr. Lawson also serves on the board of the Hugh & Ilene Lawson Charitable Organization (HILCO), which supports inclusive educational opportunities for students pursuing higher education.
高管简历
中英对照 | 中文 | 英文- Paul Glavine
Paul Glavine是该公司的联合创始人和首席运营官。他是一位连续创业者和投资者，在生物技术、采矿、技术和生命科学领域拥有丰富的经验。Glavine先生是TruVerra的联合创始人，该公司被Supreme Cannabis Company收购，后来又被Canopy Growth收购。他之前的背景是从事停车技术行业，过去5年间，他曾为1.8亿人次的并购及其他融资提供咨询服务。
Paul Glavine is a biotechnology entrepreneur and investor leading growth at Helus Pharma, a clinical stage biopharmaceutical company developing novel serotonergic agonists for mental healthcare. Under his leadership, Helus Pharma secured FDA Breakthrough Therapy Designation for HLP003 and advanced HLP004, a generalized anxiety disorder candidate, from preclinical studies into human trials. A serial entrepreneur, Mr. Glavine has raised over $500 million in capital and led mergers and acquisitions that have expanded operating businesses and therapeutic pipelines across his portfolio. He serves as Chairman of LongPoint ETFs. He is a Milken Institute Young Leader and was named to Catalyst Health's Top 40 Under 40 in Life Sciences.- Paul Glavine是该公司的联合创始人和首席运营官。他是一位连续创业者和投资者，在生物技术、采矿、技术和生命科学领域拥有丰富的经验。Glavine先生是TruVerra的联合创始人，该公司被Supreme Cannabis Company收购，后来又被Canopy Growth收购。他之前的背景是从事停车技术行业，过去5年间，他曾为1.8亿人次的并购及其他融资提供咨询服务。
- Paul Glavine is a biotechnology entrepreneur and investor leading growth at Helus Pharma, a clinical stage biopharmaceutical company developing novel serotonergic agonists for mental healthcare. Under his leadership, Helus Pharma secured FDA Breakthrough Therapy Designation for HLP003 and advanced HLP004, a generalized anxiety disorder candidate, from preclinical studies into human trials. A serial entrepreneur, Mr. Glavine has raised over $500 million in capital and led mergers and acquisitions that have expanded operating businesses and therapeutic pipelines across his portfolio. He serves as Chairman of LongPoint ETFs. He is a Milken Institute Young Leader and was named to Catalyst Health's Top 40 Under 40 in Life Sciences.
- Eric So
Eric So是该公司的联合创始人和总裁。在过去15年中，他是各种公共和私营公司的资深所有者和经营者，并在从初创企业到高增长和跨国企业的商业生命周期的各个阶段领导C级公司战略、发展和财务。他的职业生涯始于Torys LLP的公司商业、证券、金融和并购领域。
Eric So is a veteran founder and operator of various public and private companies over the last 20 years and has led corporate strategy, development and finance at all stages of the business life cycle from start up to high growth and large multi national. A trusted advisor he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm. He has focused on sectors which have profound global impact in critical areas such as mental health and addiction.- Eric So是该公司的联合创始人和总裁。在过去15年中，他是各种公共和私营公司的资深所有者和经营者，并在从初创企业到高增长和跨国企业的商业生命周期的各个阶段领导C级公司战略、发展和财务。他的职业生涯始于Torys LLP的公司商业、证券、金融和并购领域。
- Eric So is a veteran founder and operator of various public and private companies over the last 20 years and has led corporate strategy, development and finance at all stages of the business life cycle from start up to high growth and large multi national. A trusted advisor he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm. He has focused on sectors which have profound global impact in critical areas such as mental health and addiction.
- Greg Cavers
Greg Cavers拥有不同成长阶段的服务运营经验；领导业务部门的初创企业、重组、系统实施和合并整合，同时提高盈利能力，将风险降至最低，致力于满足财务报告、国际财务报告准则，以及监管报告、OSFI和MFDA的要求。
Greg Cavers has over 20 years' experience specializing in transforming and revitalizing corporate finance departments. Mr. Cavers has experience in service operations in varying stages of growth; leading business unit start ups, restructuring, system implementations and merger integrations while increasing profitability, minimizing risk and dedicated to meeting financial reporting, IFRS; as well as regulatory reporting OSFI, MFDA requirements.- Greg Cavers拥有不同成长阶段的服务运营经验；领导业务部门的初创企业、重组、系统实施和合并整合，同时提高盈利能力，将风险降至最低，致力于满足财务报告、国际财务报告准则，以及监管报告、OSFI和MFDA的要求。
- Greg Cavers has over 20 years' experience specializing in transforming and revitalizing corporate finance departments. Mr. Cavers has experience in service operations in varying stages of growth; leading business unit start ups, restructuring, system implementations and merger integrations while increasing profitability, minimizing risk and dedicated to meeting financial reporting, IFRS; as well as regulatory reporting OSFI, MFDA requirements.
- Gabriel Fahel
Gabriel Fahel拥有在快节奏和充满政治色彩的环境中管理多司法管辖区和多学科团队的广泛经验。他参与了国际法的复杂和棘手的领域，并在加拿大各级法院，包括加拿大最高法院提出了新颖的法律问题。Fahel以前是加拿大政府的法律顾问，Mundo Media Ltd.和Growpacker Inc.的总法律顾问，并担任Adam Smith International和联合国开发计划署的法律顾问。在担任这些职务之前，Fahel先生是湾街律师事务所的一名律师，从事商业诉讼和公共利益集体诉讼。他是PsyCan（The Canadian Psychedelic Businesses Association）的创始董事。他在约克大学获得文学士学位（1997年），在温莎大学法学院获得法律学士学位（2000年），在纽约大学法学院获得法律硕士学位（2002年）。
Gabriel Fahel is a seasoned legal executive and a central architect of the corporate evolution and growth of Helus Pharma. With over 25 years of experience navigating complex corporate commercial matters, government relations, and international public structures, Gabe has played a pivotal role in bridging the gap between innovative small molecule pharmaceuticals and global capital markets. Since the company's inception, he has shepherded Helus Pharma through its most transformative milestones, including leading the legal execution for more than $500 million in total capital raised and overseeing the Company's public listings on both the NYSE and Nasdaq.- Gabriel Fahel拥有在快节奏和充满政治色彩的环境中管理多司法管辖区和多学科团队的广泛经验。他参与了国际法的复杂和棘手的领域，并在加拿大各级法院，包括加拿大最高法院提出了新颖的法律问题。Fahel以前是加拿大政府的法律顾问，Mundo Media Ltd.和Growpacker Inc.的总法律顾问，并担任Adam Smith International和联合国开发计划署的法律顾问。在担任这些职务之前，Fahel先生是湾街律师事务所的一名律师，从事商业诉讼和公共利益集体诉讼。他是PsyCan（The Canadian Psychedelic Businesses Association）的创始董事。他在约克大学获得文学士学位（1997年），在温莎大学法学院获得法律学士学位（2000年），在纽约大学法学院获得法律硕士学位（2002年）。
- Gabriel Fahel is a seasoned legal executive and a central architect of the corporate evolution and growth of Helus Pharma. With over 25 years of experience navigating complex corporate commercial matters, government relations, and international public structures, Gabe has played a pivotal role in bridging the gap between innovative small molecule pharmaceuticals and global capital markets. Since the company's inception, he has shepherded Helus Pharma through its most transformative milestones, including leading the legal execution for more than $500 million in total capital raised and overseeing the Company's public listings on both the NYSE and Nasdaq.
- Aaron Bartlone
Aaron Bartlone是一位成就卓著且备受推崇的生物制药高管，在将颠覆性疗法推向全球市场方面有着令人印象深刻的记录。在加入公司之前，Aaron在UCB服务了12年，担任质量保证、患者安全和企业风险管理高级副总裁，在那里他为神经病学、胃肠病学和免疫学领域的产品提供了功能性结果、临床管线进展和监管营销批准。Aaron还担任过Cybin Inc.商业运营总裁，在那里他实现了+ Cybin Inc. 20亿美元损益的两位数增长，同时重组了业务部门并支持合规基础设施。在加入UCB之前，Aaron在礼来公司工作了14年，跨越了无数的Cybin公司，并在全球担任了跨越质量保证、监管事务和CMC产品开发的角色，在那里他将成功的神经病学、肿瘤学、糖尿病以及心血管候选药物和组合产品通过临床阶段推向全球市场。Aaron拥有扬斯敦州立大学化学与数学学士学位和圣母大学分析化学硕士学位。
Aaron Bartlone is an accomplished and highly regarded biopharmaceutical executive with an impressive track record of driving disruptive therapies to worldwide markets. Prior to joining the Company, Aaron served UCB for 12 years as Senior Vice President of Quality Assurance, Patient Safety and Enterprise Risk Management, where he delivered functional results, clinical pipeline progression and regulatory marketing approvals for products in neurology, gastroenterology and immunology. Aaron also served as President of the US Commercial Operations where he delivered double digit growth on a +US$2 billion P&L while concurrently restructuring the business units and supporting compliance infrastructure. Before UCB, Aaron spent 14 years with Eli Lilly & Company across a myriad of US and global roles spanning Quality Assurance, Regulatory Affairs and CMC Product Development, where he drove successful neurology, oncology, diabetes, and cardiovascular drug candidates and combination products through the clinical phases to global markets. Aaron holds a bachelor's degree in Chemistry & Mathematics from Youngstown State University and a master's degree in Analytical Chemistry from the University of Notre Dame.- Aaron Bartlone是一位成就卓著且备受推崇的生物制药高管，在将颠覆性疗法推向全球市场方面有着令人印象深刻的记录。在加入公司之前，Aaron在UCB服务了12年，担任质量保证、患者安全和企业风险管理高级副总裁，在那里他为神经病学、胃肠病学和免疫学领域的产品提供了功能性结果、临床管线进展和监管营销批准。Aaron还担任过Cybin Inc.商业运营总裁，在那里他实现了+ Cybin Inc. 20亿美元损益的两位数增长，同时重组了业务部门并支持合规基础设施。在加入UCB之前，Aaron在礼来公司工作了14年，跨越了无数的Cybin公司，并在全球担任了跨越质量保证、监管事务和CMC产品开发的角色，在那里他将成功的神经病学、肿瘤学、糖尿病以及心血管候选药物和组合产品通过临床阶段推向全球市场。Aaron拥有扬斯敦州立大学化学与数学学士学位和圣母大学分析化学硕士学位。
- Aaron Bartlone is an accomplished and highly regarded biopharmaceutical executive with an impressive track record of driving disruptive therapies to worldwide markets. Prior to joining the Company, Aaron served UCB for 12 years as Senior Vice President of Quality Assurance, Patient Safety and Enterprise Risk Management, where he delivered functional results, clinical pipeline progression and regulatory marketing approvals for products in neurology, gastroenterology and immunology. Aaron also served as President of the US Commercial Operations where he delivered double digit growth on a +US$2 billion P&L while concurrently restructuring the business units and supporting compliance infrastructure. Before UCB, Aaron spent 14 years with Eli Lilly & Company across a myriad of US and global roles spanning Quality Assurance, Regulatory Affairs and CMC Product Development, where he drove successful neurology, oncology, diabetes, and cardiovascular drug candidates and combination products through the clinical phases to global markets. Aaron holds a bachelor's degree in Chemistry & Mathematics from Youngstown State University and a master's degree in Analytical Chemistry from the University of Notre Dame.
- George Tziras
George Tziras，在投资银行和国际资本市场方面拥有超过15年的经验，曾任职于多家全球金融机构，包括高盛、瑞士信贷、野村、雷曼兄弟和加拿大帝国商业银行。Tziras先生从事过广泛的交易，包括债务和股权融资；合并、处置和收购；私募股权收购和债务重组。他还曾跨界多个行业，包括医疗保健。Tziras先生拥有牛津大学的学士学位和约翰霍普金斯大学的硕士学位。Tziras先生于2021年加入Small Pharma Inc，担任首席商务官，并于2022年7月20日过渡为Small Pharma Inc的首席执行官，直到该公司于2023年10月23日被公司收购。Tziras先生自2015年起担任Small Pharma Ltd（现已更名为Cybin英国有限公司）的董事。Tziras先生于2023年10月24日加入Cybin，担任董事兼首席商务官。
George Tziras has over 15 years of experience in investment banking and international capital markets having worked at a number of global financial institutions including Goldman Sachs, Credit Suisse, Nomura, Lehman Brothers and CIBC. Mr. Tziras has worked on a broad range of transactions including debt and equity financings; mergers, disposals and acquisitions; private equity buyouts and debt restructurings. He has also worked across a number of industries, including healthcare. Mr. Tziras holds a BA degree from the University of Oxford and a MA degree from Johns Hopkins. Mr. Tziras joined Small Pharma in 2021 as Chief Business Officer and on July 20, 2022, transitioned to Chief Executive Officer of Small Pharma until it was acquired by the Company on October 23, 2023. Mr. Tziras has been a director of Small Pharma Ltd (now Cybin UK Ltd. T/A Helus) since 2015. Mr Tziras joined Helus Pharma on October 24, 2023.- George Tziras，在投资银行和国际资本市场方面拥有超过15年的经验，曾任职于多家全球金融机构，包括高盛、瑞士信贷、野村、雷曼兄弟和加拿大帝国商业银行。Tziras先生从事过广泛的交易，包括债务和股权融资；合并、处置和收购；私募股权收购和债务重组。他还曾跨界多个行业，包括医疗保健。Tziras先生拥有牛津大学的学士学位和约翰霍普金斯大学的硕士学位。Tziras先生于2021年加入Small Pharma Inc，担任首席商务官，并于2022年7月20日过渡为Small Pharma Inc的首席执行官，直到该公司于2023年10月23日被公司收购。Tziras先生自2015年起担任Small Pharma Ltd（现已更名为Cybin英国有限公司）的董事。Tziras先生于2023年10月24日加入Cybin，担任董事兼首席商务官。
- George Tziras has over 15 years of experience in investment banking and international capital markets having worked at a number of global financial institutions including Goldman Sachs, Credit Suisse, Nomura, Lehman Brothers and CIBC. Mr. Tziras has worked on a broad range of transactions including debt and equity financings; mergers, disposals and acquisitions; private equity buyouts and debt restructurings. He has also worked across a number of industries, including healthcare. Mr. Tziras holds a BA degree from the University of Oxford and a MA degree from Johns Hopkins. Mr. Tziras joined Small Pharma in 2021 as Chief Business Officer and on July 20, 2022, transitioned to Chief Executive Officer of Small Pharma until it was acquired by the Company on October 23, 2023. Mr. Tziras has been a director of Small Pharma Ltd (now Cybin UK Ltd. T/A Helus) since 2015. Mr Tziras joined Helus Pharma on October 24, 2023.
- Amir Inamdar
Amir Inamdar是一位合格的精神科医生和药学医师，在临床研究和药物开发方面拥有超过25年的经验。Inamdar博士已成功推进众多候选药物，从临床前开发和早期临床试验到概念验证研究，再到成功的上市许可。他在领导全球跨职能团队开发新型药物方面拥有丰富经验，涉及一系列精神适应症，包括治疗抵抗性抑郁症、发作性睡病、焦虑症、精神分裂症、躁郁症和物质使用障碍。
Amir Inamdar is a qualified psychiatrist and pharmaceutical physician with over 25 years of experience in clinical research and drug development. Dr. Inamdar has successfully progressed numerous candidate drugs from preclinical development and early phase clinical trials to proof of concept studies and through to successful marketing authorization. He has extensive experience leading global, cross functional teams in the development of novel medications across a range of psychiatric indications, including treatment resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance use disorders.- Amir Inamdar是一位合格的精神科医生和药学医师，在临床研究和药物开发方面拥有超过25年的经验。Inamdar博士已成功推进众多候选药物，从临床前开发和早期临床试验到概念验证研究，再到成功的上市许可。他在领导全球跨职能团队开发新型药物方面拥有丰富经验，涉及一系列精神适应症，包括治疗抵抗性抑郁症、发作性睡病、焦虑症、精神分裂症、躁郁症和物质使用障碍。
- Amir Inamdar is a qualified psychiatrist and pharmaceutical physician with over 25 years of experience in clinical research and drug development. Dr. Inamdar has successfully progressed numerous candidate drugs from preclinical development and early phase clinical trials to proof of concept studies and through to successful marketing authorization. He has extensive experience leading global, cross functional teams in the development of novel medications across a range of psychiatric indications, including treatment resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance use disorders.
- Michael Halstead
Michael Halstead，拥有25年的行业经验，最近担任Intra-cellular Therapies, Inc.（“intra-cellular”）总裁。在Intra-Cellular任职期间，他在将公司从早期临床开发组织转变为完全整合的商业生物制药企业方面发挥了关键作用。他在CAPLYTA的成功开发、推出和商业化过程中发挥了重要作用（LUATEperone），该公司已获得多个适应症的批准，包括精神分裂症、双相抑郁症和重度抑郁症的辅助治疗。Halstead先生还支持推进该公司在与阿尔茨海默病相关的广泛性焦虑症和神经精神症状方面的管道项目。此外，他还管理过多次股票发行，并于2025年牵头将该公司的Cybin Inc.以146亿美元的价格出售给了强生。
Michael Halstead,has 25 years of industry experience, most recently serving as President of Intra-Cellular Therapies, Inc. ("Intra-Cellular"). During his tenure at Intra-Cellular, he played a pivotal role in transforming the company from an early-stage clinical development organization into a fully integrated commercial biopharmaceutical enterprise. He was instrumental in the successful development, launch, and commercialization of CAPLYTA (lumateperone), which has received approvals across multiple indications, including schizophrenia, bipolar depression and the adjunctive treatment of major depressive disorder. Mr. Halstead also supported the advancement of the company's pipeline programs in generalized anxiety disorder and neuropsychiatric symptoms associated with Alzheimer's disease. In addition, he managed multiple equity offerings and led the company's Cybin Inc.$14.6 billion sale to Johnson & Johnson in 2025.- Michael Halstead，拥有25年的行业经验，最近担任Intra-cellular Therapies, Inc.（“intra-cellular”）总裁。在Intra-Cellular任职期间，他在将公司从早期临床开发组织转变为完全整合的商业生物制药企业方面发挥了关键作用。他在CAPLYTA的成功开发、推出和商业化过程中发挥了重要作用（LUATEperone），该公司已获得多个适应症的批准，包括精神分裂症、双相抑郁症和重度抑郁症的辅助治疗。Halstead先生还支持推进该公司在与阿尔茨海默病相关的广泛性焦虑症和神经精神症状方面的管道项目。此外，他还管理过多次股票发行，并于2025年牵头将该公司的Cybin Inc.以146亿美元的价格出售给了强生。
- Michael Halstead,has 25 years of industry experience, most recently serving as President of Intra-Cellular Therapies, Inc. ("Intra-Cellular"). During his tenure at Intra-Cellular, he played a pivotal role in transforming the company from an early-stage clinical development organization into a fully integrated commercial biopharmaceutical enterprise. He was instrumental in the successful development, launch, and commercialization of CAPLYTA (lumateperone), which has received approvals across multiple indications, including schizophrenia, bipolar depression and the adjunctive treatment of major depressive disorder. Mr. Halstead also supported the advancement of the company's pipeline programs in generalized anxiety disorder and neuropsychiatric symptoms associated with Alzheimer's disease. In addition, he managed multiple equity offerings and led the company's Cybin Inc.$14.6 billion sale to Johnson & Johnson in 2025.
- Regina Donohue
Regina Donohue，担任首席人力资源官，在那里她建立了公司的人员战略和基础设施，并在公司过渡到商业阶段组织时管理其快速增长，推出了第一个产品，并发展到1000 +名员工。Intra-Cellular于2025年4月被强生收购。
Regina Donohue,served as Chief Human Resources Officer, where she built the company's people strategy and infrastructure, and managed its rapid growth as it transitioned into a commercial-stage organization, launched its first product, and grew to 1,000+ employees. Intra-Cellular was acquired by Johnson & Johnson in April 2025.- Regina Donohue，担任首席人力资源官，在那里她建立了公司的人员战略和基础设施，并在公司过渡到商业阶段组织时管理其快速增长，推出了第一个产品，并发展到1000 +名员工。Intra-Cellular于2025年4月被强生收购。
- Regina Donohue,served as Chief Human Resources Officer, where she built the company's people strategy and infrastructure, and managed its rapid growth as it transitioned into a commercial-stage organization, launched its first product, and grew to 1,000+ employees. Intra-Cellular was acquired by Johnson & Johnson in April 2025.